Betibeglogene autotemcel (Zynteglo)
Jump to navigation
Jump to search
Mechanism of action
Gene therapy using autologous hematopoietic stem and progenitor cells transduced with BB305 lentiviral vector.
History of changes in FDA indication
- 2022-08-17: Approved for treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell (RBC) transfusions. (Based on HGB-207 and HGB-212)
Also known as
- Generic name: beti-cel
- Brand name: Zynteglo